ASPro-PD – Neuroprogressive and Dementia Network

Ambroxol to Slow Progression in Parkinson Disease (ASPro-PD)

A new clinical trial, titled ‘Ambroxol to Slow Progression in Parkinson’s’ (ASPro-PD), is set to commence shortly. This large-scale phase 3 trial aims to determine whether ambroxol can slow or halt the progression of Parkinson’s disease. Ambroxol has been widely used to treat coughs and sore throats across Europe since 1973. More information can be found here.

This study is in setup

To find out more about this research study, please contact:
loth.sdcrn@nhs.scot
0131 537 3804

Key Staff

NDN Principal Investigator: Dr David Breen

This study is looking at patients with Parkinson’s Disease experiencing hallucinations.

CONTACT INFORMATION

Neuroprogressive & Dementia Research Network Office

Old Pharmacy Building
Western General Hospital
Edinburgh
EH4 2XU

Email: loth.sdcrn@nhs.scot

Telephone: 0131 537 3804

ABOUT US

The NRS Neuroprogressive Disease and Dementia Network team in NHS Lothian conduct commercial and investigator led studies for: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Motor Neurone Disease, dementia with Lewy bodies, Progressive Supranuclear Palsy and Multiple System Atrophy.